Case-Based Roundtable Series


Late-Stage Therapeutic Options in Lung Cancer

January 19th 2022

This roundtable series delves into therapies used for late-stage small and non–small cell lung cancer as discussed by participants at virtual live events.

Treatment With PARP Inhibitors for Patients With Ovarian Cancer

January 12th 2022

This roundtable series examines PARP inhibition as first-line maintenance therapy for patients with advanced ovarian cancer as discussed by participants at virtual live events.

Using Anti-CD38 Monoclonal Antibodies as Treatment in Multiple Myeloma

January 7th 2022

This roundtable series explores triplet and quadruplet combination therapies, including anti-CD38 monoclonal antibodies, with or without transplant in patients with multiple myeloma as discussed by participants at virtual live events.

Later-Line Choices for Patients With Metastatic TNBC

December 29th 2021

This roundtable series assists in the evaluation of therapies for patients with metastatic triple-negative breast cancer as discussed by participants at virtual live events.

Deciding Management for Early HER2-Positive Breast Cancer

December 24th 2021

This roundtable series reviews the selection of regimens for patients with HER2-positive breast cancer as discussed by participants at virtual live events.

First-Line Treatment Using Combination Therapy in Advanced RCC

December 20th 2021

This roundtable series provides insight on risk assessment and multiple therapy combinations for patients with advanced renal cell carcinoma as discussed by participants at virtual live events.

Therapeutic Options for NTRK-Mutated Thyroid Cancer

December 16th 2021

This roundtable series evaluates genomic testing and NTRK-targeted treatment in patients with thyroid cancer as discussed by participants at virtual live events.

Targeting Cancer With Tyrosine Kinase Inhibition in Frontline HCC

December 14th 2021

This roundtable series covers tyrosine kinase inhibition in the first line for patients with hepatocellular carcinoma discussed in virtual live events.

Choosing AR-Targeted Therapy in CSPC

December 3rd 2021

This roundtable series explores therapies for patients with castration-sensitive prostate cancer discussed in virtual live events.

Targeting MET Exon 14 Skipping Mutations in NSCLC

November 12th 2021

This roundtable series assesses the use of treatments targeting MET exon 14 skipping mutations in patients with non–small cell lung cancer discussed in virtual live events.